Pembrolizumab

Generic Name
Pembrolizumab
Brand Names
Keytruda
Drug Type
Biotech
Chemical Formula
-
CAS Number
1374853-91-4
Unique Ingredient Identifier
DPT0O3T46P
Background

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...

Indication

Pembrolizumab is indicated for the following conditions:

For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.

Associated Conditions
Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Associated Therapies
-
Clinical Trials
Related News

Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

First Posted Date
2024-10-15
Last Posted Date
2024-11-27
Lead Sponsor
Emory University
Target Recruit Count
28
Registration Number
NCT06636734
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

First Posted Date
2024-10-14
Last Posted Date
2024-10-14
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Target Recruit Count
150
Registration Number
NCT06640283
Locations
🇧🇷

Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, Brazil

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

First Posted Date
2024-10-11
Last Posted Date
2024-10-11
Lead Sponsor
Rima Patel
Target Recruit Count
15
Registration Number
NCT06637306
Locations
🇺🇸

Mount Sinai Health System, New York, New York, United States

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

First Posted Date
2024-10-10
Last Posted Date
2024-12-03
Lead Sponsor
Genmab
Target Recruit Count
702
Registration Number
NCT06635824
Locations
🇺🇸

Ocala Oncology Center P.L., Ocala, Florida, United States

🇺🇸

Clinical Research Alliance, Westbury, New York, United States

🇯🇵

Miyagi Cancer Center, Natori-shi, Japan

and more 2 locations

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1100
Registration Number
NCT06632327

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

First Posted Date
2024-10-04
Last Posted Date
2024-12-17
Lead Sponsor
AstraZeneca
Target Recruit Count
878
Registration Number
NCT06627647
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Trial of LNS8801 with or Without Pembrolizumab in Patients with Refractory Melanoma

First Posted Date
2024-10-03
Last Posted Date
2024-10-08
Lead Sponsor
Linnaeus Therapeutics, Inc.
Target Recruit Count
135
Registration Number
NCT06624644

A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

First Posted Date
2024-10-02
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
680
Registration Number
NCT06623422
Locations
🇺🇸

Beacon Cancer Care ( Site 0127), Post Falls, Idaho, United States

🇺🇸

Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee, United States

🇦🇺

Tasman Oncology Research ( Site 2104), Southport, Queensland, Australia

and more 6 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

First Posted Date
2024-10-01
Last Posted Date
2024-12-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
218
Registration Number
NCT06618287
Locations
🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

🇬🇧

Local Institution - 0030, London, England, United Kingdom

🇺🇸

Local Institution - 0009, Miami, Florida, United States

and more 19 locations

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

First Posted Date
2024-09-23
Last Posted Date
2024-09-23
Lead Sponsor
UNICANCER
Target Recruit Count
2454
Registration Number
NCT06606730
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy